MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
cepii_allergie.png
 
 
 
Hauptnavigation
  • Home
  • Allgemeine Informationen
  • Forschung
  • Studium & Lehre
  • FachärztInnenausbildung
 
IPA / Single View
 
Subnavigation

Research News

 

Generation of high affinity ICAM-1-specific nanobodies and evaluation of their suitability for allergy treatment

Ines Zettl, Tatiana Ivanova, Mohammed Zghaebi, Marina V. Rutovskaya, Isabella Ellinger, Oksana Goryainova, Jessica Kollárová, Sergio Villazala-Merino, Christian Lupinek, Christina Weichwald, Anja Drescher, Julia Eckl-Dorna,...[more]

 

Nothobranchius furzeri, the Turquoise Killifish: A Model of Age-Related Osteoporosis?

Maria Butylina, PhD-student in the group of Prof. Dr. Peter Pietschmann, published recently her research on Nothobranchius furzeri, the turquoise killifish, in Gerontology. [more]

 

Isolation of nanobodies with potential to reduce patients' IgE binding to the major birch pollen allergen, Bet v 1

Ines Zettl, Tatiana Ivanova, Maria R. Strobl, Christina Weichwald, Oksana Goryainova, Evgenia Khan, Marina V. Rutovskaya, Margarete Focke- Tejkl, Anja Drescher, Barbara Bohle, Sabine Flicker, Sergei V. Tillib Allergy 2022...[more]

 

Impaired Mineral Ion Metabolism in a Mouse Model of Targeted Calcium-Sensing Receptor (CaSR) Deletion from Vascular Smooth Muscle Cells

Martin Schepelmann (group Enikö Kallay) and national and international colleagues and collaborators have just published a study in the Journal of the American Society of Nephrology (JASN), one of the highest ranked and most...[more]

 

Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants

The preclinical data for a vaccine developed at MedUni Vienna to protect against SARS-CoV-2 indicates that it is effective against all SARS-CoV-2 variants known to date, including omicron - even in those who have not yet built up...[more]

 

Birch pollen allergic patients have IgE and IgG antibodies binding to diverse patterns of conformational epitopes on the major allergen, Bet v 1

Schmalz S, Mayr V, Shosherova A, Gepp B, Ackerbauer D, Sturm G, Bohle B, Breiteneder H, Radauer C. Isotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1.[more]

 

Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.

Gattinger P, Niespodziana K, Stiasny K, Sahanic S, Tulaeva I, Borochova K, Dorofeeva Y, Schlederer T, Sonnweber T, Hofer G, Kiss R, Kratzer B, Trapin D, Tauber PA, Rottal A, Körmöczi U, Feichter M, Weber M, Focke-Tejkl M,...[more]

 
Displaying results 1 to 7 out of 98
<< First < Previous 1 2 3 4 5 6 7 Next > Last >>
 
Inhaltsbereich

Isolation of nanobodies with potential to reduce patients' IgE binding to the major birch pollen allergen, Bet v 1

Ines Zettl, Tatiana Ivanova, Maria R. Strobl, Christina Weichwald, Oksana Goryainova, Evgenia Khan, Marina V. Rutovskaya, Margarete Focke- Tejkl, Anja Drescher, Barbara Bohle, Sabine Flicker, Sergei V. Tillib Allergy 2022 Jun;77(6):1751-1760. doi: 10.1111/all.15191. Epub 2021 Dec 16

Birch pollen allergy ranks among the most prevalent pollen allergies in Northern and Central Europe. Estimated 100 million individuals worldwide suffer from this IgE-mediated disease leading to clinical manifestations such as hayfever causing a major health and economic burden. Bet v 1 is the sole major birch pollen allergen. It sensitizes more than 90% of individuals allergic to birch pollen and mainly contributes to pollen-associated food allergy.
Representing such a clinically important allergen, various strategies to treat and/or cure birch pollen allergy have been elaborated in the last decades. Passive immunization with allergen-specific antibodies is one approach that recently came into the focus of researchers. Studies showed that a single injection of human monoclonal allergen-specific IgG antibodies significantly reduced allergic symptoms in birch pollen-allergic patients.
However, the production of full monoclonal antibodies in sufficient amounts is laborious and expensive.
This is the reason why we generated and isolated Bet v 1-specific nanobodies to find out if allergen-specific nanobodies have similar protective potential as monoclonal antibodies.
Therefore, a cDNA-VHH library was constructed from a camel that was immunized with Bet v 1 and screened for Bet v 1-specific binders by phage display.  Our isolated nanobodies not only recognized Bet v 1 with high affinity but cross-react with birch pollen related allergens from alder and hazel. Both characteristics defined our allergen-specific nanobodies already as suitable candidates for further investigations. More importantly, it revealed that our selected nanobodies inhibited allergic patients' polyclonal IgE binding to Bet v 1 and Bet v 1-homologues and reduced allergen-induced basophil activation.
Our study reports for the first time on allergen-specific nanobodies as useful tools for future treatment of pollen allergy.
This work was supported by the Austrian Science Fund (FWF) grants  I3946-B33, F4607, and P32953 and by the Russian Foundation for Basic Research (RFBR) grant 18-515-14003.

Link to PubMed

 

 

 
 
Drucken
 

Schnellinfo

 
-- Green IPA
-- Technology Platforms
-- Kontakt
-- News (Archiv)
-- Seminare
-- Social Life
-- Intranet Login
-- QM-Dokumente (Intranet)
-- Bildergalerie (Intranet)
-- Alumni
-- Links
 
 

Featured

 
 
 
© MedUni Wien  | 
 Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt